EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

Louis D Saravolatz, Shawn Depcinski, Mamta Sharma

Clinical Infectious Diseases · 06.01.2023 · 76 (1) · 165-171

DOI: 10.1093/cid/ciac180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.03.2022. Verfasst von Louis D Saravolatz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Thomas Mackey Center for Infectious Diseases Research, Ascension St John Hospital, Grosse Pointe Woods, Michigan, USA. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19. Die Arbeit wurde bisher 280-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration has issued an emergency use authorization for 2 oral antivirals, molnupiravir (in persons aged ≥18 years) and nirmatrelvir-ritonavir (Paxlovid) (in persons aged ≥12 years weighing ≥40 kg), for the outpatient treatment of patients with mild to moderate coronavirus disease 2019 (COVID–19) who are at risk for progression. Molnupiravir is a nucleoside analogue, whereas nirmatrelvir is a SARS-CoV-2 main protease inhibitor, and ritonavir is a human immunodeficiency virus type 1 protease inhibitor. Drug interactions are a major concern for nirmatrelvir-ritonavir. Nirmatrelvir-ritonavir demonstrated a greater risk reduction in hospitalization and death than molnupiravir compared to placebo. Both drugs need to be started within 5 days of symptoms onset and given for 5 days’ duration. This article reviews the 2 oral COVID-19 antiviral drugs including the mechanisms of action, antiviral activity, pharmacokinetics, drug interactions, clinical experience including trials, adverse events, recommended indications, and formulary considerations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19United StatesHumansAdolescentAdultRitonavirSARS-CoV-2COVID-19 Drug TreatmentDrug CombinationsLactamsLeucineNitrilesProlineCytidineHydroxylamines

Stichwörter der Autor:innen

COVID-19Paxlovidmolnupiravirnirmatrelvirritonavir

Substanzen

Antiviral AgentsRitonavirnirmatrelvir and ritonavir drug combinationDrug CombinationsLactamsLeucineNitrilesProlinemolnupiravirCytidine

Autor:innen und Institutionen

  • Thomas Mackey Center for Infectious Diseases Research, Ascension St John Hospital, Grosse Pointe Woods, Michigan, USA.
  • Ascension-St John Hospital, Grosse Pointe Woods, Michigan, USA.
  • Wayne State University School of Medicine, Detroit, Michigan, USA.
  • Central Michigan University College of Medicine, Mt Pleasant, Michigan, USA.
  • Ascension Rx Specialty Pharmacy, Grosse Pointe Woods, Michigan, USA.

Zitieren

APA

Saravolatz, L. D., Depcinski, S., & Sharma, M. (2023). Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clinical Infectious Diseases, 76(1), 165-171. https://doi.org/10.1093/cid/ciac180

Vancouver

Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clinical Infectious Diseases. 2023;76(1):165-171. doi:10.1093/cid/ciac180

BibTeX
@article{Saravolatz2023,
  author = {Saravolatz, Louis D and Depcinski, Shawn and Sharma, Mamta},
  title = {Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {1},
  pages = {165--171},
  doi = {10.1093/cid/ciac180}
}
Kostenlos starten →